Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) EBT (2016 - 2025)

Historic EBT for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$6.4 million.

  • Angiodynamics' EBT rose 4141.78% to -$6.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$27.7 million, marking a year-over-year increase of 8832.66%. This contributed to the annual value of -$34.0 million for FY2025, which is 8224.15% up from last year.
  • As of Q4 2025, Angiodynamics' EBT stood at -$6.4 million, which was up 4141.78% from -$10.8 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' EBT ranged from a high of $34.9 million in Q3 2023 and a low of -$199.7 million during Q1 2024
  • Over the past 5 years, Angiodynamics' median EBT value was -$9.4 million (recorded in 2022), while the average stood at -$17.7 million.
  • In the last 5 years, Angiodynamics' EBT skyrocketed by 35157.68% in 2023 and then tumbled by 196684.6% in 2024.
  • Angiodynamics' EBT (Quarter) stood at -$8.9 million in 2021, then decreased by 2.12% to -$9.1 million in 2022, then crashed by 39.41% to -$12.6 million in 2023, then grew by 14.03% to -$10.8 million in 2024, then soared by 41.42% to -$6.4 million in 2025.
  • Its EBT stands at -$6.4 million for Q4 2025, versus -$10.8 million for Q3 2025 and -$6.1 million for Q2 2025.